Proceedings of the 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
Vol. 5 No. s1 (2026)
Anticoagulation during anti-angiogenic cancer therapy: balancing risks of thrombosis and bleeding
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
0
Views
0
Downloads
Authors
Anti-angiogenic therapies, including agents targeting vascular endothelial growth factor or its receptors are widely used for the treatment of different types of cancer. On-target adverse events of anti-angiogenic therapies include an increased risk of bleeding due to impaired endothelial integrity and vascular regeneration. In addition, an increased risk of arterial and venous thromboembolic events has been reported for selected anti-angiogenic agents. Anticoagulation therapy, either due to pre-existing indications or for the treatment of thromboembolic events during anti-angiogenic treatment, therefore, poses a clinical challenge. In the absence of robust evidence-based guidelines and in the context of heterogeneous patient- and treatment-related risk factors, individualized assessment of both thromboembolic and bleeding risk is warranted. High-quality evidence to support clinical management in this setting remains scarce, necessitating personalized risk-benefit evaluations. In the present narrative review, we summarize available data on the risk profiles of thromboembolic and bleeding events associated with different anti-angiogenic therapies and discuss strategies for anticoagulation management in this setting.
Downloads
Download data is not yet available.
Citations
1. Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers 2022;8:11. DOI: https://doi.org/10.1038/s41572-022-00336-y
2. Verso M, Moik F, Graziani M, Cohen AT. Targeted anti-cancer agents and risk of venous thromboembolism. Haematologica 2024;109:3868-78. DOI: https://doi.org/10.3324/haematol.2023.284778
3. Haslam A, Kim MS, Prasad V. Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020. Ann Oncol 2021;32:926-32. DOI: https://doi.org/10.1016/j.annonc.2021.04.003
4. Moik F, Riedl JM, Englisch C, Ay C. Update on thrombosis risk in patients with cancer: focus on novel anticancer immunotherapies. Hamostaseologie 2024;44:40-8. DOI: https://doi.org/10.1055/a-2215-9909
5. Moik F, Ay C. Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies. Thrombosis Res 2022;213:S58-65. DOI: https://doi.org/10.1016/j.thromres.2022.01.004
6. Mulder FI, Horváth-Puhó E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021;1371959-69. DOI: https://doi.org/10.1016/S0049-3848(21)00147-X
7. Rajabi M, Mousa SA. The role of angiogenesis in cancer treatment. Biomedicines 2017;5:34. DOI: https://doi.org/10.3390/biomedicines5020034
8. Watson N, Al-Samkari H. Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy. J Thromb Haemost 2021;19:1852-63. DOI: https://doi.org/10.1111/jth.15354
9. Moik F, Horváth-Puhó E, Ay C, et al. Arterial and venous thromboembolic events in patients with cancer treated with targeted therapies: a population-based cohort study. EClinicalMedicine 2025;87:103440. DOI: https://doi.org/10.1016/j.eclinm.2025.103440
10. Unkel S, Amiri M, Benda N, et al. On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies. Pharm Stat 2019;18:166-83. DOI: https://doi.org/10.1002/pst.1915
11. Seng S, Liu Z, Chiu SK, et al. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol 2012;30:4416-26. DOI: https://doi.org/10.1200/JCO.2012.42.4358
12. Ma Z, Sun X, Zhang Y, et al. Risk of thromboembolic events in cancer patients treated with immune checkpoint inhibitors: a meta-analysis of randomized controlled trials. Thromb Haemost 2022;122:1757-66. DOI: https://doi.org/10.1055/s-0042-1749185
13. Moik F, Riedl JM, Ay C. VTE with amivantamab plus chemotherapy in NSCLC. N Engl J Med 2024;390:578-9. DOI: https://doi.org/10.1056/NEJMc2314937
14. Pandey AK, Singhi EK, Arroyo JP, et al. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension 2018;71:e1-8. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.117.10271
15. Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens 2018;12:409-25. DOI: https://doi.org/10.1016/j.jash.2018.03.008
16. Abdol Razak NB, Jones G, Bhandari M, et al. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel) 2018;10:380. DOI: https://doi.org/10.3390/cancers10100380
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42. DOI: https://doi.org/10.1056/NEJMoa032691
18. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300:2277-85. DOI: https://doi.org/10.1001/jama.2008.656
19. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9. DOI: https://doi.org/10.1093/jnci/djm086
20. Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients. J Am Heart Assoc 2017;6:e006278. DOI: https://doi.org/10.1161/JAHA.117.006278
21. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010;49(3):287-97. DOI: https://doi.org/10.3109/02841860903524396
22. Abdel-Rahman O, ElHalawani H. Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents. Crit Rev Oncol Hematol 2016;102:89-100. DOI: https://doi.org/10.1016/j.critrevonc.2016.04.003
23. Arnold D, Fuchs CS, Tabernero J, et al. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol 2017;28:2932-42. DOI: https://doi.org/10.1093/annonc/mdx514
24. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-9. DOI: https://doi.org/10.1016/S0140-6736(13)61719-5
25. Qi WX, Shen Z, Tang LN, Yao Y. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. Crit Rev Oncol Hematol 2014;92:71-82. DOI: https://doi.org/10.1016/j.critrevonc.2014.04.004
26. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24. DOI: https://doi.org/10.1056/NEJMoa065044
27. Liu B, Ding F, Zhang D, Wei GH. Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis. Cancer Chemother Pharmacol 2017;80:487-95. DOI: https://doi.org/10.1007/s00280-017-3386-6
28. Qi WX, Min DL, Shen Z, et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer 2013;132):2967-74. DOI: https://doi.org/10.1002/ijc.27979
29. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1814-23. DOI: https://doi.org/10.1056/NEJMoa1510016
30. Eswaran H, Kasthuri RR, Bendapudi PK, et al. Cabozantinib and thromboembolism in patients with cancer: a systematic review, meta-analysis and retrospective study. Blood Adv 2026;10:301-14. DOI: https://doi.org/10.1182/bloodadvances.2025018001
31. Azoulay L. Rationale, strengths, and limitations of real-world evidence in oncology: a Canadian review and perspective. Oncologis. 2022;27:e731-e8. DOI: https://doi.org/10.1093/oncolo/oyac114
32. Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet 2016;388:518-29. DOI: https://doi.org/10.1016/S0140-6736(15)01088-0
33. Ahn JW, Shalabi D, Correa-Selm LM, et al. Impaired wound healing secondary to bevacizumab. Int Wound J 2019;16:1009-12. DOI: https://doi.org/10.1111/iwj.13139
34. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305:487-94. DOI: https://doi.org/10.1001/jama.2011.51
35. Hapani S, Sher A, Chu D, Wu S. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 2010;79:27-38. DOI: https://doi.org/10.1159/000314980
36. Hang XF, Xu WS, Wang JX, et al. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2011;67:613-23. DOI: https://doi.org/10.1007/s00228-010-0988-x
37. Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther 2018;11:5059-74. DOI: https://doi.org/10.2147/OTT.S166151
38. Peng L, Bu Z, Zhou Y, et al. Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis. Tumour Biol 2014;35:9419-27. DOI: https://doi.org/10.1007/s13277-014-2189-1
39. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499-506. DOI: https://doi.org/10.1200/JCO.2012.42.8201
40. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009;10:967-74. DOI: https://doi.org/10.1016/S1470-2045(09)70222-0
41. Qi WX, Tang LN, Sun YJ, et al. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials. Ann Oncol 2013;24:2943-52. DOI: https://doi.org/10.1093/annonc/mdt292
42. Chen Q, Huang X, Lin S, et al. Does the combination of anticoagulants and angiogenesis inhibitors increase the risk of bleeding in cancer patients? Thromb Haemost 2025. DOI: https://doi.org/10.1055/a-2740-1655
43. Boileve A, Albiges L, Ducreux M, et al. Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study. Support Care Cancer 2022;31:41. DOI: https://doi.org/10.1007/s00520-022-07533-1
44. Fusillo TF, Leader A, Mantha S, et al. Bleeding in lung cancer patients receiving therapeutic anticoagulation while being treated with VEGF and EGFR inhibitors. Blood 2024;144:2632. DOI: https://doi.org/10.1182/blood-2024-202609
45. Sivakumar A, Caulfield SE, Zhang C, et al. Retrospective study of bleeding risk with concomitant vascular endothelial growth factor receptor tyrosine kinase inhibitor and anticoagulation. Oncologist 2021;26):e2061-9. DOI: https://doi.org/10.1002/onco.13897
46. Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009;14:862-70. DOI: https://doi.org/10.1634/theoncologist.2009-0071
47. Mayenga M, Falvo N, Mahé I, et al. Cancer-associated thrombosis on bevacizumab: risk of recurrence and bleeding when bevacizumab is stopped or continued. Cancers (Basel) 2023;15:3893. DOI: https://doi.org/10.3390/cancers15153893
48. Verso M, Munoz A, Agnelli G. Bleeding risk with concomitant administration of VEGF-TKIs and anticoagulant agents. Semin Oncol 2023;50:67-70. DOI: https://doi.org/10.1053/j.seminoncol.2023.05.002
49. Wang TF, Baumann Kreuziger L, et al. Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J Thromb Haemost 2021;19:2068-81. DOI: https://doi.org/10.1111/jth.15367
50. Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol 2023;34:452-67. DOI: https://doi.org/10.1016/j.annonc.2022.12.014
51. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Guideline Update. J Clin Oncol 2023;41:3063-71. DOI: https://doi.org/10.1200/JCO.23.00294
52. Gelosa P, Castiglioni L, Tenconi M, et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res 2018;135:60-79. DOI: https://doi.org/10.1016/j.phrs.2018.07.016
53. Otten LS, Piet B, van den Heuvel MM, et al. Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer. Eur Respir Rev 2022;31:220004. DOI: https://doi.org/10.1183/16000617.0004-2022
54. Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging 2022;23:e333-e465.
55. Tebbutt NC, Murphy F, Zannino D, et al. Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Ann Oncol 2011;22:1834-8. DOI: https://doi.org/10.1093/annonc/mdq702
56. Xu Y, Mallity C, Collins E, et al. Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials. Eur Heart J Cardiovasc Pharmacother 2025;10:665-75. DOI: https://doi.org/10.1093/ehjcvp/pvae068
How to Cite
1.
Vladic N, Moik F. Anticoagulation during anti-angiogenic cancer therapy: balancing risks of thrombosis and bleeding. Bleeding Thromb Vasc Biol [Internet]. 2026 Apr. 16 [cited 2026 Apr. 17];5(s1). Available from: https://www.btvb.org/btvb/article/view/452
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
